Prediction of survival benefit using an automated bone scan index in patients with castration‐resistant prostate cancer
Authors:
- 12 July 2012
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 110 (11b) , E628-E634
Abstract
Study Type – Prognosis (case series) Level of Evidence 4 What's known on the subject? and What does the study add? A bone scan index (BSI) can quantify the extent of bone involvement and response to treatment, but it has not been widely accepted, because of its time‐consuming nature. The study is the first to demonstrate that automated BSI calculated with a computer‐assisted diagnosis system is effective in judging the chemotherapeutic response of bone metastatic lesions in patients with castration‐resistant prostate cancer. OBJECTIVE: To evaluate the value of an automated bone scan index (aBSI), calculated using a computer‐assisted diagnosis system, to indicate chemotherapy response and to predict prognosis in patients with castration‐resistant prostate cancer (CRPC) with bone metastasis. PATIENTS AND METHODS: Forty‐two consecutive CRPC patients underwent taxane‐based chemotherapy between November 2004 and March 2011 at our institution. The aBSIs were retrospectively calculated at the diagnosis of CRPC and 16 weeks after starting chemotherapy. Cox proportional hazards regression models were applied to multivariate analyses with and without aBSI response in addition to the basic model. Based on the difference in the concordance index (c‐index) between each model, the prognostic relevance of adding the aBSI response was determined. RESULTS: A decrease in aBSI was found in 28 patients (66.7%), whereas a response was shown by bone scan in only 23.8% of patients. Patients with a reduction in aBSI had longer overall survival (OS) in comparison with the other patients ( P = 0.0157). Multivariate analysis without aBSI response showed that performance status ( P = 0.0182) and PSA response ( P = 0.0375) were significant prognosticators. By adding the aBSI response to this basic model, the prognostic relevance of the model was improved with an increase in the c‐index from 0.621 to 0.660. CONCLUSIONS: The aBSI reflected the chemotherapy response in bone metastasis. The index detected small changes of bone metastasis response as quantified values and was a strong prognostic indicator for patients with CRPC.Keywords
This publication has 25 references indexed in Scilit:
- EAU Guidelines on Prostate CancerEuropean Urology, 2008
- Phase-II Study of Docetaxel, Estramustine Phosphate, and Carboplatin in Patients with Hormone-Refractory Prostate CancerEuropean Urology, 2007
- Impact of Computer-Aided Detection in a Regional Screening Mammography ProgramAmerican Journal of Roentgenology, 2005
- Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: A pilot studyUrology, 2005
- State‐of‐the‐art approaches to detecting early bone metastasis in prostate cancerBJU International, 2004
- Costs of Prostate Cancer, Metastatic to the Bone, in The NetherlandsEuropean Urology, 2003
- Prostate carcinomaCancer, 2003
- Prognostic Value of Bone Scan in Patients With Metastatic Prostate Cancer Treated Initially With Androgen Deprivation TherapyJournal of Urology, 2002
- Screening Mammography with Computer-aided Detection: Prospective Study of 12,860 Patients in a Community Breast CenterRadiology, 2001
- Prognostic Significance of Extent of Disease in Bone in Patients With Androgen-Independent Prostate CancerJournal of Clinical Oncology, 1999